Skip to content

Comparing an easy-to-use swab test and ultrasound for detection of womb cancer

Prospective, interventional cohort trial of WID-easy test performance for detection of womb cancer in women with abnormal uterine bleeding

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN32260240
Enrollment
2000
Registered
2026-01-07
Start date
2026-03-02
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Womb cancer Cancer

Interventions

All eligible women will be invited to participate in the trial, with trial information sent to them with their clinic visit appointment letter. Enrolment will be done from the Urgent Suspected Cancer

Sponsors

Sola Diagnostics UK Ltd
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
45 Years to 100 Years

Inclusion criteria

Inclusion criteria: Women with a uterus aged 45 years or more referred for evaluation of abnormal uterine bleeding who are willing and able to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. Current pregnancy 2. Previous hysterectomy

Design outcomes

Primary

MeasureTime frame
Outcome positive and outcome negative participants at 3 months after WID®-easy testing. Outcome positives are defined as cases with histologically confirmed endometrial and/or cervical and/or tubal and/or ovarian cancer. Outcome negatives are defined as cases with (a) histology confirmed absence of any gynaecological cancer and (b) confirmed (imaging and/or histology) absence of gynaecological cancer.

Secondary

MeasureTime frame
Outcome positive and outcome negative participants at 12 months after WID®-easy testing. Outcome positives are defined as cases with histologically confirmed endometrial and/or cervical and/or tubal and/or ovarian cancer. Outcome negatives are defined as cases with (a) histology confirmed absence of any gynaecological cancer and (b) confirmed (imaging and/or histology) absence of gynaecological cancer.

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 14, 2026